


① RCH

Form PTO-1449  INFORMATION DISCLOSURE STATEMENT BY APPLICANT	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 94,784-L	Serial No. 09/665,358
	Applicant: Stojiljkovic et al.		
	Filing Date: September 19, 2000	Group: 1641 1647	

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date
RCH	1	5,223,409	6/29/93	Ladner et al.			
	2	4,683,195	7/28/87	Mullis et al.			
	3	4,683,202	11/27/90	Mullis et al.			
	4	6,121,037	9/19/00	Stojiljkovic et al.			
	5	5,304,487	4-19-94	Wilding et al.			

OTHER DOCUMENTS - Including Author, Title, Date, Pertinent Pages, Etc.


RCH	6	Archibald and DeVoe, (1979) FEMS Microbiol. Lett., 6, pp. 159-162.
	7	Baggs and Neilands, (1991), Microbiol. Rev., 51: 509-518.
	8	Calver et al., (1976) Can. J. Microbiol., 22, 832-838.
	9	Cornelissen et al., (1993) J. Bacteriol., 174: pp. 5788-5797.
	10	Correia et al., (1988) J. Biol. Chem., 263: 12194-12198.
	11	Coulton and Pang, (1983) Curr. Microbiol., 9: pp. 93-98.
	12	Dyer et al., (1987) Infect. Immun., 55: pp. 2171-2175.
	13	Fenno et al., (1993) Gene, 130: 81-90.
	14	Gerlach et al., (1992) Infect. Immun., 60: 3253-3261.
	15	Gotschlich et al., (1987) J. Exp. Med., 165: pp. 471-482.
	16	Heller et al., (1988) Gene, 64: pp. 147-153.
	17	Henderson and Payne, (1994) J. Bacteriol., 176: pp. 3269-3277.
	18	Hnatowich et al., (1983) Science, 220: pp. 613-615.

RECEIVED
 AUG 16 2001
 TECH CENTER 1600/2900

Examiner 	Date Considered 5/24/05
--	-------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with any communication.

(2) RH

Form PTO-1449 INFORMATION DISCLOSURE STATEMENT BY APPLICANT	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 94,784-L	Serial No. 09/665,358
		Applicant: Stojilkovic et al.	
		Filing Date: September 19, 2000	Group: 1647

OTHER DOCUMENTS - Including Author, Title, Date, Pertinent Pages, Etc.


RH	19	Holbien et al., (1981) Infect. Immun., 34: 120-125,
	20	Jarosik et al., (1994) Infect. Immun., 62: pp. 2470-2477.
	21	Kellog et al., (1963) J. Bacteriol., 85: 1274-1279.
	22	Knight et al., (1992) Mol. Microbiol., 6: pp. 1565-1573.
RH	23	Koebnik et al., (1993) Trends Microbiol., 6: pp. 1565-1573.
	24	Lee and Hill, (1992) J. Gen. Microbiol., 138: 2647-2656.
	25	Lee, (1994) Microbiol., 140: 1473-1480.
	26	Lundrigan & Kadner, (1986) J. Biol. Chem., 261: pp. 10797-10801.
	27	Martek and Lee, (1994) Infect. Immun., 62: 700-703
	28	Meares et al., (1984) Anal. Biochem., 142: 68-78.
	29	Mickelson et al., (1982) Infect. Immun., 35: pp. 915-920
↓	30	Nassif et al., (1993) Mol. Microbiol., 6: pp. 719-725

RECEIVED
 AUG 16 2001
 TECH CENTER 1600/2900

Examiner <i>R. Kayer</i>	Date Considered <i>5/24/05</i>
--------------------------	--------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with any communication.

3 RCV

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 94,784-L	Serial No. 09/665,358
INFORMATION DISCLOSURE STATEMENT BY APPLICANT 		Applicant: Stojilkovic et al.	
		Filing Date: September 19, 2000	Group: 1641 1647

OTHER DOCUMENTS - Including Author, Title, Date, Pertinent Pages, Etc.

RCV	31	Otto et al., (1992) Crit. Rev. Microbiol., 18:217-233.
	32	Pettersson et al., (1993) Infect. Immun., 61: 4724-4733.
	33	Pettersson et al., (1994) J. Bacteriol 176:pp.1764-1766.
	34	Postle, (1990) Mol. Microbiol., 133: pp. 891-898
	35	Riboli et al., (1991) Microb. Pathogen., 10: pp. 393-403
	36	Rudinger, June 1976, Peptide Hormones, pp.1-7.
	37	Saiki et al., (1988) Science, 230: 1350-1354.
	38	Schoffler and Braun, Molec. Gen. Genet., 217: pp. 378-383.
	39	Schryvers and Morris, (1988) Infect. Immun., 56: pp. 1144-1149.
	40	Schryvers and Morris, (1988) Mol. Microbiol., 2: 281-288.
	41	Schryvers et al., (1989) Infect. Immun., 57(8): pp.2425-2429.
RCV	42	Stojilkovic et al., (1995) Mol. Microbiol. 15:pp.531-541.
	43	Stroebner and Payne, (1988) Infect. Immun., 56: pp. 2891-2895
	44	Struyve et al., (1991) J. Mol. Biol., 218: 141-148
	45	Walters, (1993) <u>Pharmaceutical Biotechnology</u> , pp. 165-174
	46	Weinberg. (1984) Physiological Rev., 64: pp. 65-102
	47	West and Sparling, (1985) Infect. Immun., 47: pp. 288-294
Examiner <i>CP Hayer</i>		Date Considered <i>5/24/05</i>

RECEIVED
 AUG 16 2001
 TECH CENTER 1600/2900

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with any communication.